Bipolar-ii - Articles | CARLAT PUBLISHING

Lumateperone in Bipolar Depression

January 31, 2022

John C. Raiss, MD. Dr. Raiss has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In December 2021, the FDA approved lumateperone (Caplyta) for bipolar I and II depression, and here we report on one of the trials that led to that approval.

RESEARCH UPDATE

A Novel Treatment for Methamphetamine Use Disorder

January 31, 2022

David A. Moltz, MD.

David A. Moltz, MD. Dr. Moltz has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

With so few pharmacologic options for methamphetamine use disorder, a large trial from The New England Journal of Medicine suggest bupropion and naltrexone are worth exploring.

How to Diagnose Bipolar Disorder

November 5, 2021

Gordon Parker, MD, PhD, DSc.

Gordon Parker, MD, PhD, DSc. Scientia Professor of psychiatry at the University of New South Wales. In 2002 he founded the Black Dog Institute, a clinical research center for mood disorders. Dr. Parker’s research has focused on the phenomenology and diagnosis of depression and bipolar disorder. Dr. Parker has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Gordon Parker takes on the DSM and offers up a practical approach to diagnosing bipolar disorder. Included is a new self-rated scale that Dr. Parker developed to separate normal good moods from hypomania.

How to Treat ADHD in Bipolar Disorder

November 5, 2021

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Are stimulants risky in bipolar disorder? And which is safer – methylphenidate or amphetamine? Chris Aiken, MD, lays out a practical approach to the overlap of bipolar disorder and ADHD.

How to Diagnose ADHD in Bipolar Disorder

September 28, 2021

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Most patients with bipolar disorder have cognitive complaints, but it’s a mistake to diagnose them all with ADHD, and a mistake to miss the genuine ADHD-bipolar comorbidity as well. Inside, a step-by-step guide to teasing apart the diagnoses.

Overdiagnosis in Psychiatry

September 10, 2021

Joel Paris, MD

Joel Paris, MD

Professor emeritus at McGill University, and senior psychiatrist and research associate at Sir Mortimer B. Davis-Jewish General Hospital. Dr. Paris is the former editor of the Canadian Journal of Psychiatry and the author of 25 books including Overdiagnosis in Psychiatry, 2nd ed. (Oxford University Press; 2020). Dr. Paris has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Joel Paris explains why adult ADHD, depression, bipolar II, PTSD, and borderline personality are overdiagnosed in psychiatry at the expense of schizophrenia.

Maintenance Pharmacotherapy of Bipolar Disorder: How Long Is Long Enough?

May 4, 2021

Nicholas Rosenlicht, MD.

Nicholas Rosenlicht, MD. Dr. Rosenlicht has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Textbooks tell us that patients with bipolar I disorder need to take mood stabilizers for life. But what are the real risks of stopping these medications? A new meta-analysis provides some clarity.

CLINICAL UPDATE

How to Use Lamotrigine

January 1, 2021

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Lamotrigine is approved for the prevention of bipolar episodes, but Dr. Aiken explains why it may also treat active bipolar depression. This mood stabilizer is among the most tolerable in its class, and has additional benefits in OCD, borderline personality disorder, and depersonalization disorder.

Mood Stabilizers: What You Don’t Know Can Hurt Them

October 6, 2020

Nicholas Rosenlicht, MD.

Nicholas Rosenlicht, MD. Dr. Rosenlicht has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

There are many mood stabilizers to choose from, but which ones are the best tolerated? This meta-analysis looks at how they stack up in terms of weight gain, sedation, and overall discontinuation.

Who Should Get Lithium?

September 3, 2020

Janusz Rybakowski, MD, PhD

Janusz Rybakowski, MD, PhD

Janusz Rybakowski is a pioneer in lithium research who has authored over 500 articles on clinical psychiatry. He is a professor of psychiatry at Poznan University in Poland, former chairman of psychiatry at the Medical Academy Bydgoszcz, and author of an upcoming textbook on lithium. Dr. Rybakowski has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Some patients respond so well to lithium that they rarely need other interventions. Janusz Rybakowski sums up what we know about the optimal lithium responder, how to use this underutilized medication, and what lithium’s antiviral properties mean in the era of COVID-19.